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aureus(MRSA), streptococci and many common Gram-negative pathogens. The ob-
jective was to evaluate the efficacy of ceftaroline fosamil monotherapy versus
other antibiotics routinely used in initial empiric treatment of MRSA-suspected
CSSTI. METHODS: MEDLINE, Medline-In-Progress, EMBASE and the Cochrane Con-
trolled Trials Registry were searched to identify published randomised controlled
trials in which ceftaroline fosamil, daptomycin, linezolid, teicoplanin, tigecycline
and vancomycin (with or without a Gram-negative antibiotic) were used to treat
patients admitted to hospital with CSSTI. Primary outcomes were clinical success
at test-of-cure visit in the modified intention-to-treat (MITT) and clinically evalu-
able (CE) populations using a NMA with uninformative priors. Clinical success for
each antibiotic was reported with 95% credible intervals (CrI95%). A fixed effects
model was used. RESULTS: Thirteen studies involving five antibiotics and a total of
8,152 patients with CSSTI were included. No data were found for teicoplanin.
Pooled clinical success rates and CrI95% in the MITT population for each antibiotic
were: ceftaroline fosamil 81.2% (CrI95%: 76.8% to 85.0%), daptomycin 81.4% (CrI95%:
72.5% to 87.9%), linezolid 84.9% (CrI95%: 80.0% to 88.8%), tigecycline 79.9% (CrI95%:
74.1% to 84.7%) and vancomycin 80.4% (CrI95%: 77.9% to 82.6%). Clinical success
rates in the CE population were: ceftaroline fosamil 89.2% (CrI95%: 85.3% to 92.3%),
daptomycin 93.3% (CrI95%: 88.5% to 96.2%), linezolid 94.2% (CrI95%: 90.7% to 96.5%),
tigecycline 88.1% (CrI95%: 84.7% to 90.9%) and vancomycin 90.0% (CrI95%: 88.2% to
91.6%). CONCLUSIONS: Although limited data were identified and differences
across trials were noted, the results of this NMA suggest that ceftaroline fosamil is
comparable in efficacy to other antibiotics used in the treatment of MRSA-sus-
pected CSSTI.
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OBJECTIVES: Quadrivalent human papillomavirus (qHPV) vaccine prevents from
genital warts in addition to HPV-related cancers. Study objective was to provide
first estimates of savings offered by the reduction in GW incidence observed in
Belgium, 4 years after the introduction of the qHPV vaccine. METHODS: A retro-
spective observational study was performed using the MLOZ health care insurance
database. Number of GW was described by age-group, gender, between 2003 and
March 2011. GW cumulative incidence estimates were compared between women
vaccinated or not with qHPV vaccine from 2007 onwards. Analyses were restricted
to age-groups of women likely to have been vaccinated. Direct medical treatment
costs published were updated to €2010 using the purchasing parity power conver-
sion rates method and estimated at 324.2€/case (public health care payer
perspective).RESULTS:A total of 55,193 women aged 16-20 year-old were retrieved,
of whom 13,117 were vaccinated with qHPV vaccine. Within this age-group, 435
first GW cases were observed, 423 in the control group (non vaccinated: 1.01%) and
12 in the vaccinated group (0.09%), representing 920 GW cases/100,000 vaccinated
women avoided among this age group during a limited period of 4 years. Cumula-
tive incidence estimates of GW were also significantly lower among women vacci-
nated with qHPV vaccine compared to those that were not: 0.12% (CI: 0.07%-0.23%)
vs. 0.93% (CI: 0.85%-1.03%), relative reduction (RR): -87.1%, p0.0001. Among girls
aged 16-20 and over 4 years, direct health care cost saved were estimated at 298K€/
100,000 vaccinated girls. CONCLUSIONS: This preliminary analysis suggests that a
marked reduction of GW and related resources used in Belgium may be achievable
through qHPV vaccination. The reduction of GW and associated treatments costs
would be higher if more cohorts were considered and should become more prom-
inent in the coming years when the current and future qHPV vaccinated cohorts
will enter into the peak age of risk for GW.
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CONTRAINDICATIONS TO HEPATITIS C TREATMENT: WHICH ONES MODIFY
THE LIKELIHOOD OF VETERANS RECEIVING TREATMENT?
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OBJECTIVES: We studied the influence of absolute and relative contraindications
on likelihood of treatment with dual-therapy for chronic heptatis C (HCV) infection
in a national cohort of HCV-infected veterans. METHODS: We identified patients
with an HCV diagnosis and either laboratory confirmation or a second diagnosis
within a year. We excluded those with no encounters at least 6 months before the
first diagnosis to ensure treatment naiveté. Cox Proportional Hazards regression
models were developed with contraindications as time-varying exposures to as-
sess their influence on treatment likelihood. RESULTS: Of 318,814 previously un-
treated veterans diagnosed from 2004-2009, 101,444 (31.8%) met all criteria. Mean
(SD) age was 58.6 (8.2) years and 96.7% were male. Race was known in 51.9%; of
which most were white (49.9%) or black (40.4%). At diagnosis, most patients had
unknown genotype (56.4%) or genotype 1 (35.3%). Contraindications were present
at diagnosis in 17.2% of patients and 30.1% developed contraindications during
follow-up. Predictive models revealed that several contraindications were signifi-
cantly and independently associated with a decreased likelihood of treatment in-
cluding kidney transplant (hazards ratio [HR]0.29), thrombocytopenia (HR0.38),
acute myocardial infarction (HR0.43), iron-deficiency anemia (HR0.46), acute
coronary syndromes (HR0.62), bipolar disorder (HR0.63), hepatic decompensa-
tion (HR0.70), and retinopathy (HR0.74). Patients with a liver transplant were
much more likely to receive treatment (HR3.51). Contraindications that had no
influence on the likelihood of treatment were intractable epilepsy, pregnancy, ma-
jor depression, and hemoglobinopathies. Neutropenia, auto-immune hepatitis,
and other organ transplant had too few events and so were dropped from the
models. CONCLUSIONS: This study provides evidence that clinicians make real-
world treatment decisions for HCV based on some contraindications but not all.
Future work should examine the occurrence of adverse events or treatment failure
in contraindicated patients and explore ways to improve clinician awareness of
contraindications when making treatment decisions.
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Rotavirus vaccination in infants has been reimbursed in Belgium since November
2006 and vaccine coverage is about 85%.OBJECTIVES:To assess and to compare the
impact of mass rotavirus vaccination on the rotavirus related hospitalisations in
children5 y old pre-vaccination and up to 4 years post-introduction of the vaccine
in 9 paediatric wards in Belgium. METHODS: Stool samples for rotavirus detection
were collected from all 5y old hospitalised children. The absolute number of
rotavirus positive tests pre-vaccine launch (01/06/2004-31/05/2006) were compared
with data at launch (01/06/2006-31/05/2007), and post-launch (01/06/2007-31/05/
2011). Data are presented as a % reduction (95% CI) per year post-vaccination con-
sidering the annual average pre-vaccination period as a reference. RESULTS: The
number of rotavirus-positive stool tests in children aged 5 years decreased from
an average of 881 pre-vaccination to 600, a 32% reduction (95% CI: 29%-35%) during
the launch period, to 368 (58%, 95% CI: 55%61%) in the 1st year post-launch, to
202 (77%, 95% CI: 74%80%) in the 2nd year, 180 (80%, 95% CI: 77%82%) in the
3rd year, and to 201 (77%, 95% CI: 74%80%) in the 4th year. In addition an overall
decline (38%, 95% CI: 36%41%) in all-cause acute-gastroenteritis (AGE) related
hospital admissions is observed from 1,757 per year pre-vaccination to 1,082 per
year 4th year post-launch. The number of bed days due to AGE has fallen from 8974
pre-vaccination to 5362 (40%, 95% CI: 39%41%) post-vaccination. A reduction
from 6340 to 4894 (27%, 95% CI: 26%28%) is also seen amongst the non-rotavirus
positive cases. CONCLUSIONS: Significant declines in number of rotavirus and
all-cause AGE related hospitalisations are seen in young children after 4 years of
mass rotavirus vaccination in Belgium. A steady state may be reached after 3 years
as no further decrease in the number of rotavirus related hospitalisations is ob-
served.
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PHARMACOTHERAPY OF ACUTE BRONCHITIS IN CLINICS: RESULTS OF
PHARMACOEPIDEMICAL RESEARCH
Zaytsev A, Kulagina I
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OBJECTIVES: Perform pharmacoepidemical analysis on actual practice when using
antibacterial therapy among adults with acute bronchitis. METHODS: We have
analyzed 572 cases of acute bronchitis among patients receiving clinical treatment
in four hospitals located in Moscow, Nizhniy Novgorod, St. Petersburg and Kazan.
An individual registration folder featuring patient’s demographic data, accompa-
nying diseases, use of antimicrobial treatment, dose regimes and methods and
length of treatment was filed for pharmacoepidemical research. The average age of
patients was 39.85,7 years with 74% of men and 26% of women. RESULTS: Anti-
biotics were used in 85.7% of all cases. In Nizhniy Novgorod antimicrobial pills were
given to 85% of patients while the number of such patients in Moscow and St.
Petersburg amounted to 88.5% and 81.5% respectively. In Kazan all the patients
received antimicrobial drugs. The most frequent drugs were macrolides (45.8%),
inhibitor-protected penicillin (43.7%) and fluoroquinolines (ciprofloxacin) (4.9%).
The less frequent ones were doxycycline (1.6%) and amoxicillin (1.8%) and ampi-
cillin (2.2%). The most frequent macrolid was azitromicyn (33.7%) as well as clar-
ythromycin (8.6%) and erythromycin (3.5%). CONCLUSIONS: As a result the actual
practice of clinical treatment of acute bronchitis among adults majorly requres the
use of antibacterial wide spectrum drugs (85.7%). The frequency of such therapy
was high in all hospitals regardless of their locations. The use of antibiotics when
treating virus etiology is obviously wrong and leads to the increase of non-desired
consequences, higher cost of treatment and might be accompanied by the growing
number of antibiotic resistant microorganisms. The above-mentioned data re-
quires to create and practice methods aimed at the reduction of antimicrobial
drug-taking for patients with acute bronchitis in clinical treatments.
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OBJECTIVES: Streptococcus pneumoniae (SP) pneumonia represents substantial
morbidity and mortality worldwide. A retrospective study was conducted to de-
scribe the incidence, serotype distribution, and in-hospital mortality associated
with reportable invasive SP pneumonia in all age groups in Norway from
2007–2009. METHODS: Patients with laboratory-confirmed invasive SP pneumonia
were identified from the Norwegian Surveillance System for Communicable Dis-
eases (MSIS) database from January 2007–December 2009. Population data were
obtained from Statistics Norway. Incidence was reported annually as new cases per
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100,000 persons. RESULTS: From 2007–2009, incidence of reportable invasive SP
pneumonia decreased linearly from 11.7/100,000 to 7.1/100,000. Incidence in-
creased with age; adults aged 65 years consistently had the highest incidence
(2007: 39.4/100,000; 2009: 24.4/100,000), with the lowest rates observed in adults
aged 20–49 years (2009: 3.35/100,000). In-hospital mortality rates were 6%
throughout the study, with the highest rates in adults aged 65 years (2009: 8.8%).
SP was the most common pathogen reported (1,358/1,544 [88%] isolates). The pro-
portion of 7-valent pneumococcal conjugate vaccine (PCV7) serotypes decreased
from 46.7% to 20.1%, while the number and proportion of non-PCV7, 13-valent
pneumococcal conjugate vaccine (PCV13) serotype disease increased, led by 19A
(n7 [1.3%] to n23 [6.9%]). The most frequently identified serotypes in 2009 were
7F (16.8%), 1 (11.4%), 22F (11.4%), 4 (8.4%), 19A (6.9%), and 3 (6.6%). In children aged
0–4 years, 8, 1, and 0 cases of PCV7 invasive SP pneumonia occurred in 2007, 2008,
and 2009, respectively. PCV13 serotypes caused 64.9% of invasive SP pneumonia in
2009, the majority in adults aged60 years. CONCLUSIONS: Although incidence of
reportable invasive pneumonia decreased in Norway from 2007–2009, after the
pediatric PCV7 National Immunization Program was fully underway, substantial
disease burden remains, particularly in older adults. Almost 65% of invasive SP
pneumonia cases were caused by pneumococcal conjugate vaccine serotypes.
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OBJECTIVES: Pneumonia is associated with substantial burdens on patient mor-
bidity and mortality, and health care resources across all age groups. A retrospec-
tive database study was conducted to assess the burden of disease associated with
hospitalized all-cause pneumonia in terms of incidence, in-hospital mortality,
length-of-stay (LOS), and hospitalization cost in the Italian regions of Lombardia
and Puglia from 2007–2009. METHODS: Data were obtained from two Local Health
Units (LHUs) in Lombardia and Puglia. All patients with an ICD-9 code diagnosis of
pneumonia (480, 481, 482, 483, 484, 485, 486, and 487) from January 1, 2007–Decem-
ber 31, 2009 were included. Incidence rates were calculated based on the number of
people per LHU and reported annually as cases per 1,000 persons. RESULTS: In
total, 10,195 patients hospitalized for pneumonia were included in this study. In-
cidence of hospitalizations increased slightly from 2007–2009 (2007: 1.91/1,000;
2008: 1.86/1,000; 2009: 2.00/1,000). In children aged 0–4 years, incidence decreased
from 5.57/1,000 in 2007 to 3.85/1,000 in 2009, while incidence in adults aged 65
years increased from 5.36/1,000 to 6.59/1,000. In-hospital deaths occurred in 196
patients (5.9%) in 2007 and 202 (5.2%) patients in 2009, with the highest mortality
observed in adults aged65 years (176 patients [9.5%] and 191 [8.1%], respectively).
No in-hospital deaths occurred in children aged 0–4 years. Mean LOS was similar
(2007: 10.5 days; 2008: 10.8 days; 2009: 11.0 days), and increased with age. Mean cost
per patient was €2,966 in 2007, €3,073 in 2008, and €3,218 in 2009. CONCLUSIONS:
Reductions in hospitalized pneumonia were observed in children aged 0–4 years;
however, overall incidence of hospitalized pneumonia slightly increased during
the study period driven by increased hospitalizations in older adults. Adults aged
65 years had the highest disease burden in terms of incidence, in-hospital mor-
tality, mean hospital LOS, and costs.
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OBJECTIVES: International randomized, multicenter, double-blinded studies dem-
onstrated that boceprevir, added to peginterferon alpha-2b and ribavirin signifi-
cantly increased sustained virologic response rates over peginterferon/ribavirin
alone in treatment-naïve (SPRINT-2) and treatment-experienced (RESPOND-2)
adult patients with chronic hepatitis C virus genotype 1 infection. Our objective
was to project the reduction in the lifetime incidence of liver-related morbidity and
mortality associated with treatment with boceprevir/peginterferon/ribavirin vs.
treatment with peginterferon/ribavirin vs. no treatment. METHODS: A multi-co-
hort Markov model was developed using German life tables and baseline patient
demographics from the trials— mean age, gender, and fibrosis stage distribution.
The first part of the model simulated three strategies—treatment with boceprevir/
peginterferon/ribavirin (as defined by the European Medicines Agency), treatment
with peginterferon/ribavirin, and no treatment. The second part of the model sim-
ulated the natural history of HCV. All hepatitis C-related state transition probabil-
ities were obtained from previously published studies. Lifetime cumulative inci-
dence of decompensated cirrhosis, hepatocellular carcinoma, liver-transplant and
liver-related death was estimated. The model was validated with previously pub-
lished studies and probabilistic sensitivity analysis was performed. RESULTS: Per
10,000 treatment-experienced patients, treatment with boceprevir/peginterferon/
ribavirin vs. treatment with peginterferon/ribavirin vs. no treatment, respectively,
were associated with substantial reductions in projected cases of decompensated
cirrhosis (1082 vs. 2286 vs. 2845), hepatocellular carcinoma (719 vs. 1440 vs. 1787),
liver-transplant (154 vs. 321 vs. 398), and liver-related death (1144 vs. 2360 vs. 2920).
Likewise, substantially fewer cases of decompensated cirrhosis (1024 vs. 1835 vs.
2873), hepatocellular carcinoma (656 vs. 1161 vs. 1806), liver-transplant (146 vs. 257
vs. 402), and liver-related death (1073 vs. 1892 vs. 2954) were projected per 10,000
treatment-naïve patients. CONCLUSIONS: Boceprevir-based regimens are pro-
jected to substantially reduce the incidence of liver-related complications and
mortality in previously untreated and treatment-experienced patients chronically
infected with hepatitis C virus genotype 1 in Germany.
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OBJECTIVES: To consider reliable sources of data to assess epidemiology of hospi-
tal-acquired infections (HAI) in intensive care units (ICU).METHODS: In order to get
epidemiological data, a literature review (2002–2009) focused on bloodstream in-
fection (BSI), catheter related BSI (CR-BSI) and ventilator-associated pneumonia
(VAP) in hospital ICU in the US was performed using EMBASE database, completed
with data from Centers for Disease Control & Prevention (CDC). US hospital data-
bases (2007) were also considered to put findings in perspective: Premier Perspec-
tiveTM Hospital Database (PPHD) and State Inpatient Database (SID: part of health
care cost and utilization project (HCUP)) providing ICU data for this study.
RESULTS: The rate of ICU hospitalized patients in the US databases (9.4%) was
within the results in literature (8%-15%). The proportion of ICU patients with de-
vices was higher in literature than in SID and PPHD databases with for central line
catheters: 48%, 19%, 26.2% and for mechanical ventilation: 33%, 21.9% and 15%
respectively. CR-BSI were reported in 4.8% of ICU patients with central venous
catheter, in literature (1.4 - 5.5 /1,000 central line days), 9.4% in SID (5.7/1,000 cath-
eter/central line days) and 33.8% in PPDH*. Rate of VAP in ICU was estimated at
2.1-10.7/1,000 ventilator days in literature and 12.2/1,000 ventilator days in SID.
Proportion of VAP amongst ICU mechanically ventilated patients was similar
within the databases (12%). BSI attributable mortality was comparable in the liter-
ature (12-25%) and hospital database (24.7% in PPHD). Attributable mortality for
VAP was not found in the literature. This latter was estimated from the hospital
database (19.6% in PPHD). CONCLUSIONS: Different sources are available to esti-
mate the prevalence of HAI in ICU. Results should be interpreted with caution due
to methodology limitations (e.g. HAI case definitions). Nevertheless, real-life data-
bases appear appropriate to estimate attributable mortality of HAI in ICU. * central
venous/line catheter.
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OBJECTIVES: To evaluate treatment outcomes in tuberculosis patients with and
without diabetes mellitus. METHODS: This was a retrospective cohort study con-
ducted at respiratory clinic of Hospital Pulau Pinang (HPP), Malaysia. All Tubercu-
losis (TB) patients who were presented to the clinic from January 2006 to December
2007 were included in the study. A purpose developed valid data collection form
was used for collecting demographic and clinical data. Treatment outcomes ini-
tially recorded as cured, treatment completed, defaulted, transferred out, expired
and treatment continued were then classified into two categories; successful and
unsuccessful treatment. Cured and treatment completed patients were placed in
treatment successful category while the rest were placed in the category of unsuc-
cessful treatment. Data was analyzed by using SPSS 16®. RESULTS: Final analysis
included 1266 patients.Three hundred and thirty eight patients (26.7%) had DM
along with TB. In multivariate analysis TB-DM was more likely to be present in
Chinese (OR 1.470, p-value 0.003), married patients (OR 1.408, p-value 0.011)
and patients having age 46-60 years (OR 2.002, p-value0.001), and 60 years (OR
 1.594, p-value  0.010). Nine hundred and eighty five (78.8%) patients were suc-
cessfully treated. Successful Treatment was observed in patients having age of
46-60 years (OR 1.567, p-value 0.001), whereas male gender (OR 0.721, p-value
 0.049) and patients with relapse TB (OR  0.494, p-value  0.002) were less likely
to have successful treatment. CONCLUSIONS: In the present study Chinese ethnic-
ity, age ( 46 years) and being married were the predictors of prevalence of TB-DM.
Majority patients were successfully treated. Male gender and patients with relapse
TB were the predictors of treatment failure. No statistically significant difference in
treatment outcomes was observed between TB patients with and without diabetes
mellitus.
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OBJECTIVES:Despite the availability of highly efficacious pharmacotherapy, tuber-
culosis (TB) still remains as a major public health problem globally. The aim of the
present study was to evaluate TB treatment outcomes in four high burden TB states
of Malaysia. METHODS: This was a retrospective prospective study conducted at
TB clinics of Penang, Sabah, Sarawak and Selangor. All TB patients who were pre-
sented to the clinics from January 2006 to December 2008 were included in the
study. A purpose developed valid data collection form was used for collecting de-
mographic and clinical data. World Health Organization (WHO) defined criteria
was used for defining treatment outcomes. Data was analyzed by using SPSS 16®.
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